Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
9.76
+0.29 (3.06%)
At close: Jun 24, 2025, 4:00 PM
9.68
-0.08 (-0.82%)
After-hours: Jun 24, 2025, 7:20 PM EDT

Company Description

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.

It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.

The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals logo
Country United States
Founded 2018
IPO Date Oct 25, 2019
Industry Biotechnology
Sector Healthcare
Employees 427
CEO Steven Basta

Contact Details

Address:
100 Campus Drive, Suite 102
Florham Park, New Jersey 07932
United States
Phone 877 742 8466
Website phathompharma.com

Stock Details

Ticker Symbol PHAT
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $19.00
CIK Code 0001783183
CUSIP Number 71722W107
ISIN Number US71722W1071
Employer ID 82-4151574
SIC Code 2834

Key Executives

Name Position
Steven L. Basta M.B.A. Chief Executive Officer, President and Director
Dr. Azmi Nabulsi M.D., M.P.H. Co-Founder
Robert Breedlove Vice President of Finance and Principal Accounting Officer
Jonathan Bentley Senior Vice President and Head of Sales, Operations and Training
Bill Aprea J.D. Senior Vice President, Chief Compliance Officer and Interim General Counsel
Susan Kim Senior Vice President of Marketing
Paul Cocja Chief People Officer
Dr. Eckhard Leifke M.D., Ph.D. Chief Medical Officer
Dr. Jay Buchanan Pharm.D. Senior Vice President of Manufacturing and Supply Chain
Mark Devlin Senior Vice President of Market Access

Latest SEC Filings

Date Type Title
Jun 16, 2025 8-K Current Report
Jun 9, 2025 8-K Current Report
Jun 9, 2025 SCHEDULE 13G/A Filing
Jun 6, 2025 8-K Current Report
Jun 6, 2025 SCHEDULE 13G/A Filing
Jun 4, 2025 SCHEDULE 13G/A Filing
May 13, 2025 SCHEDULE 13D/A Filing
May 1, 2025 10-Q Quarterly Report
May 1, 2025 8-K Current Report
Apr 24, 2025 SCHEDULE 13G/A Filing